-
Company Insights
Innovation and Patenting activity of Basilea Pharmaceutica Ltd Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Basilea Pharmaceutica Ltd Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Derazantinib Hydrochloride in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Derazantinib Hydrochloride in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Derazantinib Hydrochloride in Solid Tumor Drug Details: Deranzantinib hydrchloride (ARQ-087)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ORM-5029 in Adenocarcinoma Of The Gastroesophageal Junction
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ORM-5029 in Adenocarcinoma Of The Gastroesophageal Junction report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ORM-5029 in Adenocarcinoma Of The Gastroesophageal Junction Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lisavanbulin in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lisavanbulin in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lisavanbulin in Non-Small Cell Lung Cancer Drug Details: Lisavanbulin (BAL-101553)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lisavanbulin in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lisavanbulin in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lisavanbulin in Triple-Negative Breast Cancer (TNBC) Drug Details: Lisavanbulin (BAL-101553)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lisavanbulin in Glioblastoma Multiforme (GBM)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lisavanbulin in Glioblastoma Multiforme (GBM) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lisavanbulin in Glioblastoma Multiforme (GBM) Drug Details: Lisavanbulin (BAL-101553) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Palbociclib in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Palbociclib in Metastatic Breast Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Palbociclib in Metastatic Breast Cancer Drug Details: Palbociclib (Ibrance, Agatha)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SC-291 in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SC-291 in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SC-291 in Diffuse Large B-Cell Lymphoma Drug Details: SC-291...
-
Product Insights
Community-Acquired Bacterial Pneumonia – Drugs In Development, 2023
Global Markets Direct’s, ‘Community-Acquired Bacterial Pneumonia - Drugs In Development, 2023’, provides an overview of the Community-Acquired Bacterial Pneumonia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Community-Acquired Bacterial Pneumonia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Endomyocardial (Eosinophilic) Disease – Drugs In Development, 2023
Global Markets Direct’s, ‘Endomyocardial (Eosinophilic) Disease - Drugs In Development, 2023’, provides an overview of the Endomyocardial (Eosinophilic) Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Endomyocardial (Eosinophilic) Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...